Abbvie Inc. (ABBV) has witnessed a flurry of activity with both significant ups and downs. Analysts at
Leerink have upgraded AbbVie's rating from
Market Perform to
Outperform, while Unsold shares by AbbVie insiders indicate
hesitancy. The pharmaceutical company takes a hit after their new
Schizophrenia Drug fails in two trials, however it doesn't prevent hedge funds from staking large amounts of capital on AbbVie. The company strengthens its focus on
Alzheimer's disease and the neuroscience pipeline with the acquisition of
Aliada Therapeutics. Despite the schizophrenia drug trials disappointment, the stock rating is being upgraded, suggesting investors see a prime
buy-the-dip moment. AbbVie has agreed to a
dividend hike, and they've achieved approval in Europe for the ovarian cancer drug
Elahere. The pharma stock has seen varied views - from being a no-brainer buy on a dip to being a better pick against competitors like JNJ.
Rapid research and
strategic acquisitions are driving growth, yet the failure of the schizophrenia drug trial has caused concerns amidst potential investors.
Abbvie ABBV News Analytics from Fri, 06 Sep 2024 07:00:00 GMT to Sat, 23 Nov 2024 15:20:41 GMT -
Rating 7
- Innovation 3
- Information 8
- Rumor -2
